Ankylose This! Living with Ankylosing Spondylitis

Monday, August 03, 2009

Generic versions of biologics?

While there are generic equivalents of many chemically based drugs that cost patients a fraction of the brand-name cost (thanks, I suppose, to the original drug patents expiring), this is not the case for the high-cost biologics -- like Enbrel, Humira and Remicade -- that many of us are turning to for relief. That high cost is raising the question of how long brand-name biologics can be exempt from market competition from "biosimilar" or "biogeneric" drugs -- especially in the U.S., where the high cost of drugs and cost containment are a crucial part of the health coverage debate. The Chicago Tribune has the story.

Labels: , ,

Comments on this post

Post a Comment

Links to this post

Create a Link


 
意甲联赛积分榜